We have the pleasure to inform you of our participation in the 7th International Cartilage Regeneration & Joint Preservation Society (ICRS) Summit in Catania, Italy. The summit will provide a comprehensive overview of the existing and novel cartilage regeneration approaches and will also offer insights into the personalization of joint preservation and guidelines for choosing the right therapy for the right patient.
Join us at Booth 19 from September 25 to 27, 2024, to connect and discuss the latest in joint preservation strategies. We look forward to engaging with you at the congress!
TRB will be exhibiting at the ESCRS this year and welcomes the opportunity to meet you at our booth n7 E117. We invite you to join us from 6-10 September 2024 in Barcelona to discuss the latest developments in ophthalmology and TRB’s contributions.
We are looking forward to meeting you at the Hotel Riu Plaza España in Madrid for the European Dry Eye Society Congress from June 20-22. As the EuDEC is a premier event for dry eye disease specialists we are excited to attend and share our latest efforts in improving the lives of patients suffering from DED.
We are excited to announce our participation in the upcoming Isokinetic Conference, taking place from May 25-27, 2024, at the Civitas Metropolitano Stadium in Madrid, Spain. Visit our stand at booth 25-26-27 to learn more about how our proven solutions can benefit patients and athletes alike. We look forward to connecting with professionals in the field and exploring new opportunities for collaboration.
We invite you to join over 1,500 orthopaedic surgeons, sports medicine specialists, and healthcare professionals from around the globe at the esteemed ESSKA Congress. This premier event will be held in the vibrant city of Milan, Italy. We’ll be ready to welcome you at Booth No. 4-08 from 8-10 May 2024.
You’ll have the opportunity to engage with our team, learn about the treatment of sports injuries and degenerative diseases. Don’t miss the chance to exchange insights and explore how we can work together to enhance patient care in these fields.
We look forward to seeing you there!
Come join us and the other 1200 scientists and healthcare professionals who will be attending the OARSI world congress on osteoarthritis in Vienna. We will be waiting for you at booth n°3/4 from 18-21 April to exchange with you and share how we work in helping patients suffering from this condition.
We also invite you to our TRB organised theatre session on Saturday, 20 April 2024 between 10:20-10:35 AM, where we will discuss “New insights in viscosupplementation effects on cartilage properties improvement”.
TRB had the pleasure of attending the “Sialoglycans in Development and Immunity” Conference, held in Hannover, Germany from October 9 to 11. It was an excellent event organized by Dr Martina Mühlenhoff, biochemist at the Institute of Clinical Biochemistry, and the Research Unit FOR2953 “Sialic Acid as a Regulator in Development and Immunity” of the Hannover Medical School.
One hundred sialoglycan researchers from over 10 countries convened to exchange and share their expertise. Their discussions focused on the role of sialoglycans in several key areas, including but not limited to: the functioning of the immune system, the proper formation of neuronal networks, and the maturation of the kidneys.
TRB was honored to take part in this first-time meeting in the world of sialoglycan fundamental research. It allowed its representative to be in contact with specialized researchers with diverse backgrounds and visions. We were especially proud to see the results of dedicated work of our scientific collaborations: Prof. Simonetta Sipione from the University of Alberta, Canada, and Dr. Markus Abeln, from the Hannover Medical School.
Simonetta Sipione is a renowned Professor with a special interest in researching the roles of gangliosides in neurodegeneration, neuroinflammation, and neuroprotection. With a strong biochemistry background, she seeks to decipher the molecular mechanisms of GM1 and other gangliosides in Huntington’s Disease. During the conference, she presented her latest discoveries in the understanding these mechanisms. For more details, visit her laboratory’s site, Sipione Laboratory.
Markus Abeln, a dynamic TRB partner in fundamental/scientific research, presented his recent findings on the role of monosialoganglioside (GM1) in protecting the mice embryo against the attack of the mother’s immune system. The newly revealed roles of GM1 in immunity mark a further step in comprehending this complex and potent molecule. See the related Nature article for more information.
Beyond established partnerships, the conference enabled us to explore new collaborative opportunities and delve deeper into the broader functions of sialoglycans. A highlight was the innovative work of Martina Mühlenhoff, who developed a technique uncovering the O-acetylation of sialic acids, significantly impacting their viral interactions. Read more about her pioneering research in this Nature Communications article.
TRB extends heartfelt gratitude to the organizers for welcoming us into this vibrant, expert community. Immersed in the evolving world of sialoglycans and gangliosides, we gained a deeper appreciation of GM1 and its pivotal role in the sialoglycans’ family. We eagerly anticipate next year’s conference, where we hope to uncover more breakthroughs in this field.
Find out more about the fascinating world of GM1 and its implications in health and science.
It is with great pleasure that we celebrate the remarkable milestone of two decades of TRB France. We stand as one of the first companies in France to introduce intra-articular injections for osteoarthritis and ophthalmic drops containing hyaluronic acid for dry eyes. TRB Chemedica France, a subsidiary of the Swiss biotechnology group TRB Chemedica International, specializing in hyaluronic acid solutions for ophthalmology, rheumatology, orthopedics, and sports medicine, is proud to announce the launch of its updated website.
For over 20 years, TRB France has consistently developed and marketed hyaluronic acid-based solutions for ophthalmic and intra-articular use. Our range of products in the fields of rheumatology, orthopedics, and sports medicine includes OSTENIL® and VISCOSEAL®, both based on hyaluronic acid derived from fermentation, designed for intra-articular injections to combat osteoarthritis.
In the realm of ophthalmology, our HYLOVIS® product line, also based on hyaluronic acid from fermentation, is tailored for treating symptoms of dry eye and ocular surface lesions.
Our expert team of 25 dedicated professionals is committed to listening to healthcare professionals and their patients, ensuring that our products meet the highest standards of quality and efficacy.
Explore our website today to learn more about our products and the difference they can make in the fields of ophthalmology, rheumatology, orthopedics, and sports medicine.
TRB Chemedica is set to attend the upcoming CPhI Worldwide Congress, a premier international event for the pharmaceutical industry, to showcase our range of high-quality pharmaceutical products and strong distribution network.
As a long-term manufacturer of Hyaluronic Acid, Diacerein and GM1 Ganglioside products, we strive to provide patients across the globe the opportunity to access our products. Our enduring and robust partnerships with well-established agents ensure our presence in over 70 countries. However, we are always looking to expand our network even further. We invite you to check out our interactive map to see if we are distributed in your country.
Moreover, our expertise in manufacturing, promoting, distributing and selling pharmaceutical products in the therapeutic areas of rheumatology, ophthalmology and neurology pushes us to always look for additional innovative solutions for patients.
The CPHI Worldwide Congress will offer an excellent opportunity for prospective collaborators and distributors to engage with us, learn about our products, and discuss potential partnerships so please feel free to visit us at booth 2T69.
You are about to leave the TRB corporate website. This link will take you to a local TRB website. Medical practices and regulations can be different from one country to another.
As a result, the medical information provided in the site which you are going to visit may not be appropriate for product use in your country.
CONTINUE